By re-analysing a previously published DLBCL cohort (275 patients)7, we observed that mutations were more frequently identified in CREBBP than in EP300 (11.7% vs. 3.3%, Fig. 5A), which is in agreement with previous studies17. This evidence concerns the gene EP300 and diffuse large B-cell lymphoma.